drugset / Trial / NCT00057681

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

NCT00057681 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.

Timeline

Start
2003-02
Primary completion
2008-12
Completion
2008-12

Outcome

Mixed primary results

paper Primary outcome measures were the Clinical Global Impressions for Bipolar Illness Improvement-Mania and the Modified Side Effects Form for Children and Adolescents. PMID 22213771 ↗

paper Higher response rates occurred with risperidone vs lithium (68.5% vs 35.6%; χ(2)(1) = 16.9, P < .001) and vs divalproex sodium (68.5% vs 24.0%; χ(2)(1) = 28.3, P < .001). PMID 22213771 ↗

paper Increased weight gain, body mass index, and prolactin level occurred with risperidone vs lithium PMID 22213771 ↗

paper and vs divalproex sodium (F(1,212) = 34.7, P < .001; F(1,212) = 45.3, P < .001; and F(1,213) = 209.4, P < .001, respectively). PMID 22213771 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Carbonate Unknown — —
Subject Risperidone Other / unclassified 2 mg —
Subject Risperidone Other / unclassified 3 mg —
Subject Valproate Small molecule — —

Indications